Navigation Links
EntreMed to Present at BIO CEO and Investor Conference
Date:2/5/2008

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 11-13, 2008. Mr. Burns' presentation is scheduled for Tuesday, February 12, 2008 at 2:45 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &

Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. EntreMed Appoints Senior Vice President of Research and Development
4. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
10. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
11. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):